Rhizen today announced the approval of IND application by the U.S. FDA to study its oral DHODH inhibitor for SARS-CoV-2 infection.... Dec 04
The partnership will address novel therapies and E3 Degraders against difficult-to-drug targets... Dec 04
-Advertisements-